Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Delivery of gene targeting siRNAs to breast cancer cells using a multifunctional peptide complex that promotes both targeted delivery and endosomal release.

Bjorge JD, Pang A, Fujita DJ.

PLoS One. 2017 Jun 30;12(6):e0180578. doi: 10.1371/journal.pone.0180578. eCollection 2017.

2.

Src regulates the activity of the ING1 tumor suppressor.

Yu L, Thakur S, Leong-Quong RY, Suzuki K, Pang A, Bjorge JD, Riabowol K, Fujita DJ.

PLoS One. 2013 Apr 9;8(4):e60943. doi: 10.1371/journal.pone.0060943. Print 2013.

3.

A truncated fragment of Src protein kinase generated by calpain-mediated cleavage is a mediator of neuronal death in excitotoxicity.

Hossain MI, Roulston CL, Kamaruddin MA, Chu PW, Ng DC, Dusting GJ, Bjorge JD, Williamson NA, Fujita DJ, Cheung SN, Chan TO, Hill AF, Cheng HC.

J Biol Chem. 2013 Apr 5;288(14):9696-709. doi: 10.1074/jbc.M112.419713. Epub 2013 Feb 11.

4.

SRC is dephosphorylated at tyrosine 530 in human colon carcinomas.

Zhu S, Bjorge JD, Fujita DJ.

Chin J Cancer Res. 2011 Sep;23(3):229-31. doi: 10.1007/s11670-011-0229-6.

5.

Inhibition of Lck: evidence for a novel natural Src family kinase inhibitor.

Zhu S, Fujita DJ, Wang JH.

J Enzyme Inhib Med Chem. 2012 Aug;27(4):546-52. doi: 10.3109/14756366.2011.601304. Epub 2011 Aug 10.

PMID:
21827365
6.

Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line.

Bjorge JD, Pang AS, Funnell M, Chen KY, Diaz R, Magliocco AM, Fujita DJ.

PLoS One. 2011 Apr 26;6(4):e19309. doi: 10.1371/journal.pone.0019309.

7.
8.

REAP: A two minute cell fractionation method.

Suzuki K, Bose P, Leong-Quong RY, Fujita DJ, Riabowol K.

BMC Res Notes. 2010 Nov 10;3:294. doi: 10.1186/1756-0500-3-294.

9.

PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation.

Zhu S, Bjorge JD, Fujita DJ.

Cancer Res. 2007 Nov 1;67(21):10129-37.

10.

Decreased CHK protein levels are associated with Src activation in colon cancer cells.

Zhu S, Bjorge JD, Cheng HC, Fujita DJ.

Oncogene. 2008 Mar 27;27(14):2027-34. Epub 2007 Oct 15.

PMID:
17934522
11.

C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases.

Chong YP, Chan AS, Chan KC, Williamson NA, Lerner EC, Smithgall TE, Bjorge JD, Fujita DJ, Purcell AW, Scholz G, Mulhern TD, Cheng HC.

J Biol Chem. 2006 Nov 3;281(44):32988-99. Epub 2006 Sep 7. Erratum in: J Biol Chem. 2015 Jan 2;290(1):240.

12.

SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis.

Babic I, Cherry E, Fujita DJ.

Oncogene. 2006 Aug 17;25(36):4955-64. Epub 2006 Mar 27.

PMID:
16568089
13.
14.

A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity.

Chong YP, Mulhern TD, Zhu HJ, Fujita DJ, Bjorge JD, Tantiongco JP, Sotirellis N, Lio DS, Scholz G, Cheng HC.

J Biol Chem. 2004 May 14;279(20):20752-66. Epub 2004 Feb 25.

15.
16.

Selected glimpses into the activation and function of Src kinase.

Bjorge JD, Jakymiw A, Fujita DJ.

Oncogene. 2000 Nov 20;19(49):5620-35. Review.

18.

Human autoantibodies to a novel Golgi protein golgin-67: high similarity with golgin-95/gm 130 autoantigen.

Eystathioy T, Jakymiw A, Fujita DJ, Fritzler MJ, Chan EK.

J Autoimmun. 2000 Mar;14(2):179-87.

PMID:
10677249
19.

Identification and characterization of a novel Golgi protein, golgin-67.

Jakymiw A, Raharjo E, Rattner JB, Eystathioy T, Chan EK, Fujita DJ.

J Biol Chem. 2000 Feb 11;275(6):4137-44.

20.

cSrc is a major cytosolic tyrosine kinase in vascular tissue.

Oda Y, Renaux B, Bjorge J, Saifeddine M, Fujita DJ, Hollenberg MD.

Can J Physiol Pharmacol. 1999 Aug;77(8):606-17.

PMID:
10543724
22.

Activating SRC mutation in a subset of advanced human colon cancers.

Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ.

Nat Genet. 1999 Feb;21(2):187-90.

PMID:
9988270
23.

Common in vitro substrate specificity and differential Src homology 2 domain accessibility displayed by two members of the Src family of protein-tyrosine kinases, c-Src and Hck.

Sicilia RJ, Hibbs ML, Bello PA, Bjorge JD, Fujita DJ, Stanley IJ, Dunn AR, Cheng HC.

J Biol Chem. 1998 Jul 3;273(27):16756-63.

24.

Effect of heparin on phosphorylation site specificity of neuronal Cdc2-like kinase.

Qi Z, Zhu X, Goedert M, Fujita DJ, Wang JH.

FEBS Lett. 1998 Feb 20;423(2):227-30.

25.

Association of neurofilament proteins with neuronal Cdk5 activator.

Qi Z, Tang D, Zhu X, Fujita DJ, Wang JH.

J Biol Chem. 1998 Jan 23;273(4):2329-35.

26.

Overexpression of normal c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential.

Irby R, Mao W, Coppola D, Jove R, Gamero A, Cuthbertson D, Fujita DJ, Yeatman TJ.

Cell Growth Differ. 1997 Dec;8(12):1287-95.

27.

Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells.

Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP, Jove R.

Cell Growth Differ. 1997 Dec;8(12):1267-76.

28.
29.

Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding.

Bellagamba C, Hubaishy I, Bjorge JD, Fitzpatrick SL, Fujita DJ, Waisman DM.

J Biol Chem. 1997 Feb 7;272(6):3195-9.

30.
31.

Activation of human pp60c-src.

Bjorge JD, O'Connor TJ, Fujita DJ.

Biochem Cell Biol. 1996;74(4):477-84. Review.

PMID:
8960354
32.

Modulation of annexin II tetramer by tyrosine phosphorylation.

Hubaishy I, Jones PG, Bjorge J, Bellagamba C, Fitzpatrick S, Fujita DJ, Waisman DM.

Biochemistry. 1995 Nov 7;34(44):14527-34.

PMID:
7578058
33.

An aberrant lck mRNA in two human T-cell lines.

Vogel LB, Arthur R, Fujita DJ.

Biochim Biophys Acta. 1995 Nov 7;1264(2):168-72.

PMID:
7495859
34.

Characterization of two activated mutants of human pp60c-src that escape c-Src kinase regulation by distinct mechanisms.

Bjorge JD, Bellagamba C, Cheng HC, Tanaka A, Wang JH, Fujita DJ.

J Biol Chem. 1995 Oct 13;270(41):24222-8.

36.

Mechanism of c-SRC activation in human melanocytes: elevated level of protein tyrosine phosphatase activity directed against the carboxy-terminal regulatory tyrosine.

O'Connor TJ, Bjorge JD, Cheng HC, Wang JH, Fujita DJ.

Cell Growth Differ. 1995 Feb;6(2):123-30. Erratum in: Cell Growth Differ 1995 Apr;6(4):484.

37.
38.

Phosphorylation of the epidermal growth factor receptor during internalization in A-431 cells.

Nesterov A, Lysan S, Vdovina I, Nikolsky N, Fujita DJ.

Arch Biochem Biophys. 1994 Sep;313(2):351-9.

PMID:
8080283
39.
40.
42.
43.

Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation.

Bjorge JD, Chan TO, Antczak M, Kung HJ, Fujita DJ.

Proc Natl Acad Sci U S A. 1990 May;87(10):3816-20.

45.

Transient expression analysis of the reticuloendotheliosis virus long terminal repeat element.

Ridgway AA, Kung HJ, Fujita DJ.

Nucleic Acids Res. 1989 Apr 25;17(8):3199-215.

46.

Coordinate alteration of pp60c-src abundance and c-src RNA expression in human neuroblastoma variants.

Veillette A, O'Shaughnessy J, Horak ID, Israel MA, Yee D, Rosen N, Fujita DJ, Kung HJ, Biedler JL, Bolen JB.

Oncogene. 1989 Apr;4(4):421-7.

PMID:
2470006
47.
49.
50.

Supplemental Content

Loading ...
Support Center